BACKCRC Microbial Marker
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 21 November 2022]
Invitation for Expression of Interest for “CRC Microbial Marker”
We are inviting expressions of interest (EoI) for commercializing “CRC Microbial Marker” technology. The innovation is developed by Professor NG Siew Chien, Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 22/MED/1152).
The Technology
Colorectal cancer (CRC) is one of the most common malignancies worldwide. The gold standard of colorectal cancer screening is colonoscopy. However, it is costly and invasive. Fecal immunochemical test (FIT) is a commonly used non-invasive test, but the sensitivity, especially for precancerous lesion, is unsatisfactory. The purpose of this invention is to define a novel microbial marker for the prediction of colorectal cancer and adenoma. Although microbial markers for colorectal cancer and adenoma have previously been identified, this invention provided a novel microbial marker, which can potentially improve the sensitivity and specificity, when can be used alone or in combination, and by applying a new algorithm.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
CRC Microbial Marker
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 21 November 2022]
Invitation for Expression of Interest for “CRC Microbial Marker”
We are inviting expressions of interest (EoI) for commercializing “CRC Microbial Marker” technology. The innovation is developed by Professor NG Siew Chien, Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 22/MED/1152).
The Technology
Colorectal cancer (CRC) is one of the most common malignancies worldwide. The gold standard of colorectal cancer screening is colonoscopy. However, it is costly and invasive. Fecal immunochemical test (FIT) is a commonly used non-invasive test, but the sensitivity, especially for precancerous lesion, is unsatisfactory. The purpose of this invention is to define a novel microbial marker for the prediction of colorectal cancer and adenoma. Although microbial markers for colorectal cancer and adenoma have previously been identified, this invention provided a novel microbial marker, which can potentially improve the sensitivity and specificity, when can be used alone or in combination, and by applying a new algorithm.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
N/A
Esther Tang
Office of Research and Knowledge Transfer Services
NG Siew Chien
CHAN Ka Leung
LIANG Qiaoyi
ZHOU Tong
N/A